NEW YORK, June 29, 2015 /PRNewswire/ -- About RLS
RLS is a neurological disease; it is also known as Willis-Ekbom disease. People with RLS experience an overwhelming desire to move their legs. It leads to an unpleasant pain in the limbs, leading to a disturbance in sleep pattern of patients. The condition aggravates at night or when the person is at rest. It occurs in both genders, but higher prevalence is seen in women than men. It affects people of all ages but mostly affecting the middle-aged and elderly people. Its common symptoms are uncomfortable itching pain in the legs, leading to a disruption in the sleep pattern and ultimately affecting the quality of life of individuals. The precise cause of RLS is not known but with the extensive investigations done in the field, it is believed to be due to predisposing genetic factors or due to low levels of iron in the brain or due to the disturbances in the dopaminergic balance. Till date, there is no specific cure for the disorder. The drugs present in the market help in the symptomatic treatment of the disorder and in relieving the uneasiness caused due to this disorder.
Technavio's analysts forecast the global RLS market to grow at a CAGR of 11.46% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global RLS market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of RLS.
Technavio's report, the Global RLS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and APAC and EMEA; it also covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
- Americas
- APAC
- EMEA
Key vendors
- Boehringer Ingelheim
- GlaxoSmithKline
- UCB
- XenoPort
Other prominent vendors
- Alexza Pharmaceuticals
- Astellas Pharma
- Axxonis Pharma
- Bayer Healthcare
- Impax Pharmaceuticals
- Luitpold Pharmaceuticals
- Merz Pharmaceuticals
- Mundipharma
- Newron Pharmaceuticals
- Serina Therapeutics
- Teva Neuroscience
Market driver
- High unmet medical needs
- For a full, detailed list, view our report
Market challenge
- Unknown disease etiology
- For a full, detailed list, view our report
Market trend
- Expected entry of drugs with multiple mechanisms and novel technologies
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Read the full report: http://www.reportlinker.com/p03034183-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article